XGN Exagen Forecast, Technical & Fundamental Analysis
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand... Show more
XGN is expected to report earnings to rise 11.76% to -18 cents per share on August 04
Q2'26
Est.
$-0.19
Q1'26
Beat
by $0.05
Q4'25
Missed
by $0.01
Q3'25
Missed
by $0.15
Q2'25
Missed
by $0.06
The last earnings report on May 11 showed earnings per share of -17 cents, beating the estimate of -21 cents. With 76.09K shares outstanding, the current market capitalization sits at 109.44M.
A.I. Advisor
published General Information
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
A.I.dvisor tells us that XGN and QDEL have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and QDEL's prices will move in lockstep.
Momentum Indicator for XGN turns positive, indicating new upward trend
XGN saw its Momentum Indicator move above the 0 level on July 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in of 217 cases, the price rose further within the following month. The odds of a continued upward trend are .
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 45 cases where XGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on July 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .
XGN moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.582) is normal, around the industry mean (69.994). P/E Ratio (0.000) is within average values for comparable stocks, (159.234). XGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.659). XGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (1.516) is also within normal values, averaging (8.241).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
